雪榕生物(300511) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥566,499,913.52, a decrease of 5.72% compared to ¥600,852,768.17 in the same period last year[8] - Net profit attributable to shareholders was ¥101,367,147.34, down 40.30% from ¥169,805,933.35 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥84,346,680.30, reflecting a decline of 51.98% compared to ¥175,658,147.06 in the previous year[8] - Basic earnings per share decreased to ¥0.24, down 40.00% from ¥0.40 in the previous year[8] - Diluted earnings per share also fell to ¥0.22, a decrease of 45.00% compared to ¥0.40 in the same period last year[8] - The weighted average return on equity was 4.85%, down from 9.30% year-on-year, a decline of 4.45%[8] - The company reported a net profit margin improvement, with net profit for the period reflecting a positive trend despite revenue decline[49] Cash Flow and Liquidity - The net cash flow from operating activities was ¥94,171,489.26, a significant drop of 55.16% from ¥210,012,722.59 in the same quarter last year[8] - Cash and cash equivalents decreased by 40.50% to CNY 452.10 million, primarily due to loan repayments and funding for investment projects[18] - The company's cash and cash equivalents decreased to approximately CNY 452.1 million from CNY 759.9 million at the end of 2020, representing a decline of about 40.4%[39] - Total cash and cash equivalents at the end of the quarter stood at 455,792,498.39 CNY, down from 510,734,470.23 CNY year-over-year[59] - The net increase in cash and cash equivalents was -304,099,422.19 CNY, contrasting with an increase of 232,936,760.02 CNY in the same period last year[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,539,961,256.98, a slight decrease of 0.54% from ¥4,564,612,500.09 at the end of the previous year[8] - The company's total assets amounted to approximately CNY 4.54 billion, a slight decrease from CNY 4.56 billion at the end of 2020[39] - The total liabilities amounted to 2,541,797,703.73 CNY, reflecting a slight increase from the previous year[66] - The total current liabilities of the company were approximately CNY 585.1 million, down from CNY 650 million, a decrease of about 10%[40] Research and Development - R&D expenses increased by 58.03% to CNY 47.59 million, reflecting higher investment in research and development[18] - The company's research and development expenses increased to CNY 4.05 million in Q1 2021, compared to CNY 3.01 million in the same period last year, reflecting a focus on innovation[53] Market and Competition - The company faces risks of declining gross margin and profits due to increased competition in the domestic edible mushroom market and potential underperformance of its overseas production base in Thailand[23] - The company plans to strengthen marketing efforts and enhance brand recognition to mitigate risks from intensified market competition[20] Investment and Projects - The company has increased its investment in construction projects, with ongoing projects valued at CNY 207.11 million, a 69.68% increase from the previous period[18] - The project for the Thai edible mushroom factory has not yet commenced, with a total investment commitment of 20 million RMB[31] - The Dezhou project has seen 62.93% of its 25 million RMB investment completed, with 6.67 million RMB already invested[31] Regulatory and Compliance - The company received approval from the China Securities Regulatory Commission for a specific stock issuance, indicating compliance with regulatory requirements[28] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[35] - The company has not utilized any idle raised funds for temporary liquidity supplementation during the reporting period[33] Financial Management - The total amount of raised funds is 58.5 million RMB, with 8.24 million RMB invested in the current quarter[31] - Cumulative changes in the use of raised funds amount to 18.68 million RMB, representing 31.93% of the total raised funds[31] - The company implemented the new leasing standards starting January 1, 2021, affecting its financial statements[68]